首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1410146

總體基因體學市場：2023年至2028年預測

Metagenomics Market - Forecasts from 2023 to 2028

出版日期: 2023年12月19日 | 出版商:

Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

總體基因體學市場預計在預測期內將以 13.26% 的複合年成長率成長。

總體基因體學是指透過定序直接從環境或臨床樣本中獲得的遺傳物質的科學研究。總體基因體學在多個領域都有應用，包括環境研究、臨床診斷、藥物研發、生物技術、食品和營養研究以及其他專業領域。總體基因體學產業的成長主要是由該領域持續的技術進步以及藥物研發和臨床診斷的改進所推動的。

蓬勃發展的藥物研發正在推動總體基因體學市場的成長。

總體基因體學用於藥物研發發現，因為它能夠識別新的微生物基因和可能成為潛在候選藥物的天然產物。總體基因體學透過分析不同環境中的不同微生物群落，能夠發現具有治療特性的生物活性化合物。鼓勵探索開拓的微生物生物多樣性的有利政府舉措和投資正在推動人們對透過總體基因體學進行藥物研發發現的興趣。例如，2023 年 3 月，加拿大政府向加拿大關鍵藥物計劃撥款 8,050 萬加元（5,900 萬美元），以加強亞伯達的藥物研究、商業化和製造。

技術進步正在推動總體基因體學市場的擴張

隨著定序技術和生物資訊學工具的不斷進步使總體基因體學研究更加高效和更具成本效益，總體基因體學行業正在經歷顯著成長。研究人員和工業界現在可以利用這些尖端工具更深入地研究複雜的微生物群落。例如，2023 年 2 月，Tecan Group 和 Oxford Nanopore Technologies 建立了聯合夥伴關係，透過簡化高通量、自動化工作流程的流程來增強奈米孔文庫的製備。 LSK114 代表了傳統定序平台的重大進步，因為它能夠對天然長 DNA 片段進行定序。

臨床診斷的改進正在推動總體基因體學的發展。

總體基因體學在臨床診斷中發揮著重要作用，因為它能夠全面了解人體中存在的微生物群落。總體基因體學有助於了解這些微生物與宿主健康之間的相互作用，從而改善疾病識別、治療策略和個人化醫療。臨床診斷領域正在經歷快速成長，製藥公司和政府的投資增加加速了對總體基因體學的需求。例如，2021 年 11 月，美國衛生與公眾服務部 (HHS) 宣布投資 6.5 億美元用於快速診斷檢測，以擴大 COVID-19 檢測的範圍。

預計亞太地區將主導總體基因體學市場。

由於亞太地區高度重視藥物研發和相關投資，預計將佔據很大的市場佔有率。例如，2023年6月，一項新的國家藥物研發化學舉措MedChem Australia將啟動醫學研究未來基金（MRFF），該基金旨在加速藥物研發進展並增強國家在藥物研發化學方面的能力，接受975萬美元。此外，2022年5月，韓國衛生福利部宣布向製藥業投資8,778億韓元（6.93億美元），以加強新藥研發工作並加強製藥業的勞動力。

高昂的初始成本限制了總體基因體學市場的成長。

宏基因組研究需要使用最先進的研究設備、先進的定序技術和複雜的資料分析方法，這不可避免地需要大量的資金。對於小型研究機構和公司來說，這些高昂的成本可能是採用總體基因體學作為研究方法的主要障礙。例如，僅全基因組定序的成本就約為 25,000 盧比（338 美元）至 50,000 盧比（676 美元），這進一步增加了科學界更廣泛採用的挑戰。

公司產品

CFX 即時 PCR 檢測系統： Bio-Rad 實驗室提供 CFX 即時 PCR 檢測系統。這些系統結合了 2 至 5 色復用、先進的光學技術以及熱感梯度的精確溫度控制。具有這些功能的 qPCR 系統能夠靈敏、可靠地檢測單重和多重即時 PCR 反應，對於尋求準確、高效分析遺傳物質的各個領域的研究人員來說非常有價值，它已成為一種工具。
QIAGEN CLC Genomics Workbench Premium： QIAGEN CLC Genomics Workbench Premium 提供全面的總體基因體學和微生物組分析工具，以滿足不同的生物資訊需求。這種先進的軟體有助於對微生物組的詳細探索、分離株的表徵、支持功能總體基因體學研究以及抗藥性細菌的鑑定。憑藉其廣泛的功能，CLC Genomics Workbench Premium 成為研究人員尋找強大且多功能工具來揭示複雜微生物群落及其功能的重要解決方案。

Metagenomics refers to the scientific investigation of genetic material obtained directly from environmental or clinical samples via sequencing. Metagenomics finds diverse applications across various fields, including environmental research, clinical diagnostics, drug discovery, biotechnology, food and nutrition studies, and other specialized areas. Metagenomics industry growth is primarily driven by improved drug discovery and clinical diagnostics, alongside continuous technological advancements in the field.

Booming drug discovery bolsters the metagenomics market growth.

Metagenomics is used in drug discovery due to its ability to identify novel microbial genes and natural products that can serve as potential drug candidates. By analyzing diverse microbial communities in various environments, metagenomics enables the discovery of bioactive compounds with therapeutic properties. Favorable government initiative and investments to encourage the exploration of untapped microbial biodiversity has fuelled the interest in drug discovery through metagenomics. For instance, in March 2023, to bolster drug research, commercialization, and manufacturing in the Alberta province, the Canadian government allocated 80.5 million Canadian dollars ($59 million) to the Canadian Critical Drug Initiative.

Technological advancements drive the metagenomics market expansion.

The metagenomics industry has experienced significant growth owing to continuous advancements in sequencing technologies, and bioinformatics tools which have enhanced the efficiency and cost-effectiveness of metagenomics studies. Researchers and industries can now harness these cutting-edge tools to delve deeper into complex microbial communities. For instance, in February 2023, Tecan Group and Oxford Nanopore Technologies formed a collaborative partnership to enhance nanopore library preparation by streamlining the process for high-throughput and automated workflows. The LSK114 represents a significant advancement over conventional sequencing platforms as it enables the sequencing of native, long fragments of DNA.

Improved clinical diagnostics drive metagenomics growth.

Metagenomics plays a crucial role in clinical diagnostics due to its ability to provide comprehensive insights into the microbial communities present in the human body. Metagenomics aids in understanding the interplay between these microorganisms and the host's health, leading to improved disease identification, treatment strategies, and personalized medicine. The field of clinical diagnostics is experiencing rapid growth, driven by increased investments from pharmaceutical companies, and the government which is accelerating metagenomics demand. For instance, in November 2021, an investment of $650 million in rapid diagnostic testing was announced by the US Department of Health and Human Services (HHS) to expand access to COVID-19 tests.

Asia-Pacific is expected to dominate the metagenomics market.

The Asia Pacific will account for a significant share of the market due to the region's significant focus on drug discovery and the accompanying investments. For instance, in June 2023, MedChem Australia, a new national medicinal chemistry initiative, received $9.75 million from the Medical Research Future Fund (MRFF), which aims to foster advancements in drug discovery and strengthen the country's capabilities in the field of medicinal chemistry. Also, in May 2022, the Korean Ministry of Health and Welfare announced an investment of 877.8 billion won ($693 million) in the pharmaceutical industry, aimed at bolstering research and development efforts for new drugs and strengthening the workforce in the sector.

High initial costs restrain the metagenomics market growth.

Metagenomic research demands the utilization of cutting-edge laboratory equipment, highly advanced sequencing technologies, and intricate data analysis methodologies, which inevitably results in significant financial outlays. For smaller research institutions and companies, these substantial expenses can pose a major obstacle to embracing metagenomics as a research approach. As an illustration, the cost of whole genome sequencing alone can range from approximately 25,000 Rs (USD 338) to 50,000 Rs (USD 676), further contributing to the challenge of broader adoption in the scientific community.

Key Developments

April 2023: PacBio, a renowned provider of precise and reliable sequencing solutions, unveiled its latest offering, the high-throughput (HT) Nanobind DNA Extraction kits. These advanced kits have been specifically developed to empower researchers with the ability to efficiently extract high-quality DNA from a diverse array of samples within a high-throughput environment. The kits boast a user-friendly and swift protocol, ensuring seamless compatibility with automation platforms offered by leading providers, further enhancing the efficiency and convenience of the DNA extraction process for researchers.
March 2023: Illumina Inc., a prominent player in DNA sequencing and array-based technologies, introduced its latest Illumina Complete Long Read technology-based assay. This high-performance, long-read, human whole-genome sequencing (WGS) assay marks a significant advancement as it grants users the unique capability of accessing both long- and short-read data using a single Illumina instrument. The new technology streamlines the workflow with significantly reduced DNA input requirements, setting it apart from other long-read offerings and making it an innovative and accessible solution for researchers.
February 2022: Yorkshire Water, in collaboration with Aqua Enviro, the wastewater technical consultancy owned by SUEZ, introduced an innovative metagenomics project aimed at monitoring and optimizing performance in wastewater treatment works. Through genetic sequencing technology, the project will provide Yorkshire Water with valuable insights into the various bacterial populations at their sites and the factors influencing their efficiency during the EBPR upgrades. This cutting-edge approach promises to enhance their understanding of microbial dynamics, enabling more effective control and management of wastewater treatment processes.

Company Products

CFX Real-Time PCR Detection Systems: Bio-Rad Laboratories offers the CFX Real-Time PCR Detection Systems, which are highly robust and adaptable instruments. These systems incorporate 2-5 color multiplexing, advanced optical technology, and precise temperature control with thermal gradients. With their capabilities, the qPCR systems enable sensitive and dependable detection of both singleplex and multiplex real-time PCR reactions, making them a valuable tool for researchers in various fields seeking accurate and efficient analysis of genetic material.
QIAGEN CLC Genomics Workbench Premium: The QIAGEN CLC Genomics Workbench Premium provides comprehensive metagenomics and microbiome analysis tools, catering to diverse bioinformatics requirements. This advanced software facilitates in-depth exploration of microbiomes, characterizes isolates, supports functional metagenomics studies, and aids in resistance identification. With its wide array of functionalities, the CLC Genomics Workbench Premium proves to be an indispensable solution for researchers seeking robust and versatile tools to unravel the complexities of microbial communities and their functions.

Segmentation

By Product

Kits & Reagents
Sequencing & Data Analytics Services
Software

By Technology

Shotgun Sequencing
16S Sequencing
Whole Genome Sequencing
Others

By Application

Environmental
Clinical Diagnostics
Drug Discovery
Biotechnology
Food & Nutrition
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. METAGENOMICS MARKET, BY PRODUCT

5.1. Introduction
5.2. Kits & Reagents
5.3. Sequencing & Data Analytics Services
5.4. Software

6. METAGENOMICS MARKET, BY TECHNOLOGY

6.1. Introduction
6.2. Shotgun Sequencing
6.3. 16S Sequencing
6.4. Whole Genome Sequencing
6.5. Others

7. METAGENOMICS MARKET, BY APPLICATION

7.1. Introduction
7.2. Environmental
7.3. Clinical Diagnostics
7.4. Drug Discovery
7.5. Biotechnology
7.6. Food & Nutrition
7.7. Others

8. METAGENOMICS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others